» Articles » PMID: 18842709

Immunomic Analysis of the Repertoire of T-cell Specificities for Influenza A Virus in Humans

Overview
Journal J Virol
Date 2008 Oct 10
PMID 18842709
Citations 123
Authors
Affiliations
Soon will be listed here.
Abstract

Continuing antigenic drift allows influenza viruses to escape antibody-mediated recognition, and as a consequence, the vaccine currently in use needs to be altered annually. Highly conserved epitopes recognized by effector T cells may represent an alternative approach for the generation of a more universal influenza virus vaccine. Relatively few highly conserved epitopes are currently known in humans, and relatively few epitopes have been identified from proteins other than hemagglutinin and nucleoprotein. This prompted us to perform a study aimed at identifying a set of human T-cell epitopes that would provide broad coverage against different virus strains and subtypes. To provide coverage across different ethnicities, seven different HLA supertypes were considered. More than 4,000 peptides were selected from a panel of 23 influenza A virus strains based on predicted high-affinity binding to HLA class I or class II and high conservancy levels. Peripheral blood mononuclear cells from 44 healthy human blood donors were tested for reactivity against HLA-matched peptides by using gamma interferon enzyme-linked immunospot assays. Interestingly, we found that PB1 was the major target for both CD4(+) and CD8(+) T-cell responses. The 54 nonredundant epitopes (38 class I and 16 class II) identified herein provided high coverage among different ethnicities, were conserved in the majority of the strains analyzed, and were consistently recognized in multiple individuals. These results enable further functional studies of T-cell responses during influenza virus infection and provide a potential base for the development of a universal influenza vaccine.

Citing Articles

Effect of XBB.1.5-adapted booster vaccination on the imprinting of SARS-CoV-2 immunity.

Pusnik J, Monzon-Posadas W, Osypchuk E, Dubiel A, Baum M, Fehring P NPJ Vaccines. 2024; 9(1):231.

PMID: 39572559 PMC: 11582569. DOI: 10.1038/s41541-024-01023-7.


Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus.

Vieira Antao A, Oltmanns F, Schmidt A, Viherlehto V, Irrgang P, Rameix-Welti M Front Immunol. 2024; 15:1376395.

PMID: 38975350 PMC: 11224462. DOI: 10.3389/fimmu.2024.1376395.


Influenza Virus-Derived CD8 T Cell Epitopes: Implications for the Development of Universal Influenza Vaccines.

Kim S, Espano E, Padasas B, Son J, Oh J, Webby R Immune Netw. 2024; 24(3):e19.

PMID: 38974213 PMC: 11224667. DOI: 10.4110/in.2024.24.e19.


Nucleoprotein as a Promising Antigen for Broadly Protective Influenza Vaccines.

Rak A, Isakova-Sivak I, Rudenko L Vaccines (Basel). 2023; 11(12).

PMID: 38140152 PMC: 10747533. DOI: 10.3390/vaccines11121747.


Validation of Multi-epitope Peptides Encapsulated in PLGA Nanoparticles Against Influenza A Virus.

Heng W, Lim H, Tan K, Poh C Pharm Res. 2023; 40(8):1999-2025.

PMID: 37344603 DOI: 10.1007/s11095-023-03540-x.


References
1.
Powell T, Strutt T, Reome J, Hollenbaugh J, Roberts A, Woodland D . Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol. 2007; 178(2):1030-8. DOI: 10.4049/jimmunol.178.2.1030. View

2.
Bui H, Sidney J, Peters B, Sathiamurthy M, Sinichi A, Purton K . Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics. 2005; 57(5):304-14. DOI: 10.1007/s00251-005-0798-y. View

3.
Yewdell J . Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity. 2006; 25(4):533-43. DOI: 10.1016/j.immuni.2006.09.005. View

4.
Scheibenbogen C, Lee K, Mayer S, Stevanovic S, Moebius U, Herr W . A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res. 1997; 3(2):221-6. View

5.
Oseroff C, Kos F, Bui H, Peters B, Pasquetto V, Glenn J . HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci U S A. 2005; 102(39):13980-5. PMC: 1236582. DOI: 10.1073/pnas.0506768102. View